FTD
62 programs · 61 companies
Programs
62
Companies
61
Trials
75
MOAs
41
IL-13iFXIaiAnti-AβTNFiSOS1iHER2WRNiCGRPantRAS(ON)iKRASG12Ci
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7975 | Phase 3 | FXIa | ||
| NVS-6360 | Approved | CD38 | ||
| ABB-8696 | Phase 3 | BCMA | ||
| AZN-7403 | Phase 2/3 | FGFR | ||
| Doxarapivir | Phase 3 | KRASG12C | ||
| Datobrutinib | Phase 3 | Aβ | ||
| Pemitapinarof | Approved | KRASG12C | ||
| INC-2432 | Phase 2 | CD47 | ||
| Fixatuximab | Preclinical | CFTR | ||
| Pexaosocimab | NDA/BLA | PLK4 | ||
| 369-789 | Phase 3 | PI3Kα | ||
| Tezetapinarof | Phase 3 | VEGF | ||
| FHT-3384 | NDA/BLA | JAK2 | ||
| PAS-2221 | Preclinical | GPRC5D | ||
| SGM-7896 | Preclinical | CD3 | ||
| Talainavolisib | Phase 2/3 | PD-L1 | ||
| Sotobrutinib | NDA/BLA | BTK | ||
| NCI-IIT-252 | Approved | RET | ||
| SAM-IIT-637 | Phase 2/3 | GLP-1R | ||
| FRE-IIT-381 | Phase 2 | KRASG12C | ||
| GIM-IIT-993 | NDA/BLA | PLK4 | ||
| Nirainavolisib | Phase 3 | IL-13 | ||
| Nidafutibatinib | NDA/BLA | EZH2 | ||
| Terazasiran | Phase 2 | TROP-2 | ||
| Teratenlimab | Preclinical | JAK2 | ||
| Zanulemzoparlimab | Phase 3 | AHR | ||
| Lisosertib | Phase 1 | Nectin-4 | ||
| Zenoglumide | Preclinical | Cl18.2 | ||
| Adagranaritide | Phase 2 | CD20 | ||
| Ivocapivasertib | Phase 1 | FLT3 | ||
| GAL-3172 | Preclinical | CFTR | ||
| Lirainavolisib | Preclinical | TIGIT | ||
| BIO-6952 | NDA/BLA | KRASG12D | ||
| ABB-879 | Phase 1 | WEE1 | ||
| 151-9555 | Phase 2/3 | B7-H3 | ||
| Lisosertib | Phase 1 | CD3 | ||
| AJA-3524 | Phase 1/2 | FXIa | ||
| IMM-2921 | Phase 1/2 | JAK2 | ||
| Mavurapivir | Phase 1 | GLP-1R | ||
| Fixaderotide | Phase 2/3 | B7-H3 | ||
| PSI-4605 | Preclinical | BCL-2 | ||
| 415-3545 | Phase 2/3 | PD-L1 | ||
| Mirinesiran | Phase 2 | FcRn | ||
| 051-5335 | Phase 3 | JAK1 | ||
| Lisosacituzumab | Phase 1/2 | LAG-3 | ||
| STA-6655 | NDA/BLA | CD38 | ||
| 4D-3071 | Approved | BCMA | ||
| Doxacilimab | Preclinical | CD19 | ||
| Kematinib | Phase 3 | WRN | ||
| Pexainavolisib | Approved | BCMA | ||
| BWA-1517 | Approved | Aβ | ||
| 417-3039 | Phase 2 | SHP2 | ||
| SLN-6859 | Phase 2 | GPRC5D | ||
| REA-6162 | Preclinical | JAK2 | ||
| Lisoderotide | Phase 3 | TNFα | ||
| Datoinavolisib | NDA/BLA | BCMA | ||
| Mavuzumab | NDA/BLA | IL-23 | ||
| Rilunaritide | Phase 1 | Aβ | ||
| FRO-9633 | Phase 3 | SGLT2 | ||
| Teraosocimab | Approved | C5 | ||
| ZEN-2386 | Phase 3 | PCSK9 | ||
| Fixazasiran | Phase 2/3 | PD-L1 |
Trials (75)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07345133 | RHH-7975 | Phase 3 | Terminated |
| NCT08141551 | NVS-6360 | Approved | Active |
| NCT03552475 | NVS-6360 | Approved | Recruiting |
| NCT03319163 | NVS-6360 | Approved | Recruiting |
| NCT05964791 | NVS-6360 | Approved | Active |
| NCT07544494 | ABB-8696 | Phase 3 | Recruiting |
| NCT05157902 | AZN-7403 | Phase 2/3 | Active |
| NCT05152548 | Doxarapivir | Phase 3 | Not yet recr... |
| NCT07973951 | Doxarapivir | Phase 3 | Not yet recr... |
| NCT04216486 | Doxarapivir | Phase 3 | Completed |
| NCT03343567 | Datobrutinib | Phase 3 | Terminated |
| NCT05455573 | Datobrutinib | Phase 3 | Completed |
| NCT08641356 | Datobrutinib | Phase 3 | Not yet recr... |
| NCT07807439 | Pemitapinarof | Approved | Recruiting |
| NCT08838499 | Pemitapinarof | Approved | Recruiting |
| NCT04989521 | Fixatuximab | Preclinical | Active |
| NCT08448577 | Pexaosocimab | NDA/BLA | Terminated |
| NCT08930071 | Tezetapinarof | Phase 3 | Recruiting |
| NCT06009027 | Tezetapinarof | Phase 3 | Not yet recr... |
| NCT07377268 | Tezetapinarof | Phase 3 | Not yet recr... |